Download MendeleyDiscovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET Bromodomains.
Taylor, A.M., Vaswani, R.G., Gehling, V.S., Hewitt, M.C., Leblanc, Y., Audia, J.E., Bellon, S., Cummings, R.T., Cote, A., Harmange, J.C., Jayaram, H., Joshi, S., Lora, J.M., Mertz, J.A., Neiss, A., Pardo, E., Nasveschuk, C.G., Poy, F., Sandy, P., Setser, J.W., Sims, R.J., Tang, Y., Albrecht, B.K.(2016) ACS Med Chem Lett 7: 145-150
- PubMed: 26985289
- DOI: https://doi.org/10.1021/ml500411h
- Primary Citation of Related Structures:
4X2I, 4Z1Q, 4Z1S - PubMed Abstract:
Inhibition of the bromodomains of the BET family, of which BRD4 is a member, has been shown to decrease myc and interleukin (IL) 6 in vivo, markers that are of therapeutic relevance to cancer and inflammatory disease, respectively. Herein we report substituted benzo[b]isoxazolo[4,5-d]azepines and benzotriazolo[4,3-d][1,4]diazepines as fragment-derived novel inhibitors of the bromodomain of BRD4. Compounds from these series were potent and selective in cells, and subsequent optimization of microsomal stability yielded representatives that demonstrated dose- and time-dependent reduction of plasma IL-6 in mice.
Organizational Affiliation:
Constellation Pharmaceuticals , 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States.
